AR111752A1 - Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos - Google Patents

Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos

Info

Publication number
AR111752A1
AR111752A1 ARP180101158A ARP180101158A AR111752A1 AR 111752 A1 AR111752 A1 AR 111752A1 AR P180101158 A ARP180101158 A AR P180101158A AR P180101158 A ARP180101158 A AR P180101158A AR 111752 A1 AR111752 A1 AR 111752A1
Authority
AR
Argentina
Prior art keywords
btla
antibodies against
agonist antibodies
lymphocyte attenuator
antibodies
Prior art date
Application number
ARP180101158A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR111752A1 publication Critical patent/AR111752A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP180101158A 2017-05-19 2018-05-03 Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos AR111752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
AR111752A1 true AR111752A1 (es) 2019-08-14

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101158A AR111752A1 (es) 2017-05-19 2018-05-03 Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos

Country Status (26)

Country Link
US (2) US10604573B2 (https=)
EP (1) EP3625257A1 (https=)
JP (2) JP6790304B2 (https=)
KR (3) KR102294051B1 (https=)
CN (3) CN117402244A (https=)
AR (1) AR111752A1 (https=)
AU (2) AU2018269585B2 (https=)
BR (1) BR112019021547A2 (https=)
CA (2) CA3064518A1 (https=)
CL (1) CL2019003215A1 (https=)
CO (1) CO2019012756A2 (https=)
CR (1) CR20190521A (https=)
DO (1) DOP2019000293A (https=)
EA (1) EA201992460A1 (https=)
EC (1) ECSP19082184A (https=)
JO (1) JOP20190261A1 (https=)
MA (1) MA49133A (https=)
MX (1) MX381033B (https=)
MY (2) MY198277A (https=)
NZ (1) NZ758360A (https=)
PE (1) PE20191843A1 (https=)
PH (1) PH12019502575A1 (https=)
SA (1) SA519410534B1 (https=)
TW (4) TWI804044B (https=)
WO (1) WO2018213113A1 (https=)
ZA (1) ZA201906954B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
JP2023546713A (ja) * 2020-10-23 2023-11-07 アナプティスバイオ インコーポレイティッド Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法
US20250304693A1 (en) * 2022-01-29 2025-10-02 Hifibio, Inc. Anti-btla antibodies and uses thereof in treating cancer
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells
WO2026053130A1 (en) * 2024-09-03 2026-03-12 Mirobio Limited Anti-btla antibodies and uses of the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
EP1560593B1 (en) * 2002-10-25 2016-04-20 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP2097447A4 (en) * 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
BR112012007875A2 (pt) * 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
EP3383908A1 (en) * 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)

Also Published As

Publication number Publication date
MX2019013604A (es) 2019-12-18
CA3064518A1 (en) 2018-11-22
MY198277A (en) 2023-08-18
TW201946932A (zh) 2019-12-16
US10604573B2 (en) 2020-03-31
CA3184628A1 (en) 2018-11-22
TWI747043B (zh) 2021-11-21
US20180334502A1 (en) 2018-11-22
WO2018213113A1 (en) 2018-11-22
AU2021277743A1 (en) 2021-12-23
BR112019021547A2 (pt) 2020-05-12
KR20190140969A (ko) 2019-12-20
US20200239578A1 (en) 2020-07-30
JP7072622B2 (ja) 2022-05-20
KR20220158847A (ko) 2022-12-01
PE20191843A1 (es) 2019-12-31
AU2018269585B2 (en) 2021-09-02
MY197425A (en) 2023-06-16
TWI804044B (zh) 2023-06-01
ZA201906954B (en) 2021-06-30
JP2020518288A (ja) 2020-06-25
JP2021019642A (ja) 2021-02-18
KR20210106033A (ko) 2021-08-27
ECSP19082184A (es) 2019-11-30
TW201904991A (zh) 2019-02-01
CN117402244A (zh) 2024-01-16
JOP20190261A1 (ar) 2019-11-05
SA519410534B1 (ar) 2023-11-08
EA201992460A1 (ru) 2020-03-18
AU2018269585A1 (en) 2019-10-31
EP3625257A1 (en) 2020-03-25
CN110621699A (zh) 2019-12-27
TW202334237A (zh) 2023-09-01
PH12019502575A1 (en) 2020-07-13
CN117402245A (zh) 2024-01-16
US11396545B2 (en) 2022-07-26
NZ758360A (en) 2022-10-28
DOP2019000293A (es) 2019-12-15
CR20190521A (es) 2020-01-06
CN110621699B (zh) 2023-10-31
TWI677504B (zh) 2019-11-21
KR102294051B1 (ko) 2021-08-27
MX381033B (es) 2025-03-12
JP6790304B2 (ja) 2020-11-25
MA49133A (fr) 2020-03-25
CL2019003215A1 (es) 2020-04-13
CO2019012756A2 (es) 2020-01-17
TW202233681A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
AR111752A1 (es) Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos
CY1123409T1 (el) Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων)
CO2017006740A2 (es) Anticuerpos anti–cd79b
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX2017003784A (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
MX2019006734A (es) Sistemas y metodos para secuenciar receptores de linfocitos t, y usos de estos.
MX2019000641A (es) Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
MX2019011225A (es) Células t modificadas por el receptor de antígeno quimérico dirigidas a cs1 para el tratamiento de la amiloidosis al.
MX386643B (es) Tratamiento contra enfermedades autoinmunitarias con combinaciones de agonistas rxr y hormonas tiroideas.
UY35327A (es) ?4,5-dihidro-1,2,4-oxadiazoles disustituidos en 3,5 y composiciones y métodos para controlar plagas de nematodos?.
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
BR112017020513A2 (pt) método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe
MX2016016664A (es) Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
AR129996A2 (es) Anticuerpos dirigidos contra il-33 y sus usos
BR112017010481A2 (pt) agonista parcial de receptor de insulina, composição, dímeros de análogo de insulina e de insulina, método para tratar diabetes, usos de um agonista parcial de receptor de insulina e de um composto, e, composto.
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
ECSP17039183A (es) Agonistas parciales del receptor de insulina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal